Rice Hall James & Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.7M | Buy |
638,233
+13,688
| +2% | +$379K | 0.95% | 31 |
|
|
2025
Q1 | $13.9M | Sell |
624,545
-18,207
| -3% | -$404K | 0.82% | 38 |
|
|
2024
Q4 | $12.7M | Sell |
642,752
-6,878
| -1% | -$136K | 0.7% | 43 |
|
|
2024
Q3 | $16.2M | Buy |
649,630
+49,000
| +8% | +$1.22M | 0.88% | 29 |
|
|
2024
Q2 | $11.2M | Sell |
600,630
-18,168
| -3% | -$339K | 0.67% | 44 |
|
|
2024
Q1 | $12.2M | Sell |
618,798
-17,231
| -3% | -$340K | 0.7% | 41 |
|
|
2023
Q4 | $11.2M | Sell |
636,029
-14,337
| -2% | -$251K | 0.65% | 44 |
|
|
2023
Q3 | $11.3M | Sell |
650,366
-9,758
| -1% | -$169K | 0.72% | 41 |
|
|
2023
Q2 | $9.29M | Buy |
660,124
+4,468
| +0.7% | +$62.9K | 0.53% | 51 |
|
|
2023
Q1 | $7.05M | Sell |
655,656
-41,506
| -6% | -$447K | 0.4% | 60 |
|
|
2022
Q4 | $10.4M | Sell |
697,162
-52,771
| -7% | -$791K | 0.6% | 48 |
|
|
2022
Q3 | $9.63M | Sell |
749,933
-64,740
| -8% | -$831K | 0.56% | 49 |
|
|
2022
Q2 | $7.89M | Buy |
814,673
+2,751
| +0.3% | +$26.7K | 0.38% | 64 |
|
|
2022
Q1 | $8.07M | Buy |
811,922
+99,115
| +14% | +$985K | 0.32% | 74 |
|
|
2021
Q4 | $8.39M | Sell |
712,807
-24,567
| -3% | -$289K | 0.3% | 72 |
|
|
2021
Q3 | $8.4M | Buy |
737,374
+3,008
| +0.4% | +$34.3K | 0.31% | 71 |
|
|
2021
Q2 | $10.2M | Buy |
734,366
+68,013
| +10% | +$947K | 0.36% | 66 |
|
|
2021
Q1 | $12.3M | Buy |
666,353
+66,836
| +11% | +$1.24M | 0.4% | 61 |
|
|
2020
Q4 | $10.6M | Buy |
+599,517
| New | +$10.6M | 0.37% | 62 |
|